Get the Stockscreener App
0.9551
6.36%
-0.0649
After Hours:
.95
-0.0051
-0.53%
Mustang Bio Inc stock is traded at $0.9551, with a volume of 169.58K.
It is down -6.36% in the last 24 hours and down -27.09% over the past month.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
See More
Previous Close:
$1.02
Open:
$1.02
24h Volume:
169.58K
Relative Volume:
0.45
Market Cap:
$5.56M
Revenue:
-
Net Income/Loss:
$-23.42M
P/E Ratio:
-0.0122
EPS:
-78
Net Cash Flow:
$-16.67M
1W Performance:
-7.27%
1M Performance:
-27.09%
6M Performance:
-89.21%
1Y Performance:
-95.96%
1-Day Range:
$0.9522
$1.0254
1-Week Range:
$0.9522
$1.0999
52-Week Range:
$0.9522
$31.00
Mustang Bio Inc Stock (MBIO) Company Profile
Name
Mustang Bio Inc
Sector
Industry
Phone
(781) 652-4500
Address
377 PLANTATION STREET, WORCESTER, NY
Compare MBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MBIO
Mustang Bio Inc
|
0.9551 | 5.56M | 0 | -23.42M | -16.67M | -78.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.20 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
525.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
326.09 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
551.22 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
242.07 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Mustang Bio Inc Stock (MBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-18-21 | Initiated | BTIG Research | Buy |
| Oct-02-20 | Initiated | B. Riley FBR | Buy |
| Nov-20-19 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-19 | Initiated | H.C. Wainwright | Buy |
| Jun-21-19 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-21-17 | Initiated | Oppenheimer | Outperform |
View All
Mustang Bio Inc Stock (MBIO) Latest News
Mustang Bio (NASDAQ:MBIO) Shares Down 5.1% – What’s Next? - Defense World
ASCO: Kite’s Glioblastoma CAR-T Highlights Solid Tumor Progress - insights.citeline.com
Pre-market Movers: LIMN, KRON, HSDT, CBUS... - RTTNews
Why MongoDB Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket - Benzinga
CAR T Cell Therapy Market Projected to Witness Massive Growth - openPR.com
Layoff Tracker: Keros Cuts 45% of Workforce Along With Pulmonary Hypertension Drug - BioSpace
Mustang Bio Reports Improved Financials Amid Strategic Adjustments - TipRanks
Mustang Bio (NASDAQ:MBIO) Rating Increased to Hold at Wall Street Zen - Defense World
Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights - GlobeNewswire
Asia-Pacific Personalized Cell Therapy Market Report - openPR.com
Arvinas (NASDAQ:ARVN) and Mustang Bio (NASDAQ:MBIO) Financial Contrast - Defense World
Geode Capital Management LLC Purchases 38,951 Shares of Mustang Bio, Inc. (NASDAQ:MBIO) - Defense World
Cell Therapy Market Growth Set to Surge Significantly during 2025 – 2032 - newstrail.com
Closing Bell Recap: Mustang Bio Inc (MBIO) Ends at 1.22, Reflecting a -1.61 Downturn - DWinneX
Mustang Bio stock plunges to 52-week low of $2.6 amid sharp decline - MSN
Mustang Bio stock plunges to 52-week low of $1.12 - Investing.com Australia
Mustang Bio stock plunges to 52-week low of $1.12 By Investing.com - Investing.com South Africa
Financial Analysis: Bio-Key International Inc (BKYI)’s Ratios Unveil Key Insights - DWinneX
Cell Therapy Market Future Path and Key Opportunities 2025 – 2032 - newstrail.com
Mustang Bio (MBIO) Sells Facility to AbbVie for $1 Million - GuruFocus
Mustang Bio Inc: Rising -98.18% from 52-Week Low, Can the Stock Stay Afloat? - investchronicle.com
Mustang Bio (MBIO) Regains Nasdaq Compliance - GuruFocus
Now Is The Time To Build A Position In Mustang Bio Inc (NASDAQ:MBIO) - Marketing Sentinel
What to expect from MBIO’s earnings report this quarter? - uspostnews.com
Mustang Bio stock hits 52-week low at $1.20 amid sharp decline - Investing.com Canada
Mustang Bio stock hits 52-week low at $1.20 amid sharp decline By Investing.com - Investing.com South Africa
Fortress Biotech Inc. (FBIO) reports earnings - Quartz
Mustang Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Mustang Bio Inc. (MBIO) reports earnings - Quartz
MUSTANG BIO, INC. SEC 10-K Report - TradingView
Mustang Bio stock plunges to 52-week low of $1.35 By Investing.com - Investing.com Australia
Mustang Bio stock plunges to 52-week low of $1.35 - Investing.com India
Fortress Biotech partners with Partex for AI-driven drug discovery - Investing.com
Car T Cell Therapy Market Demand, Statistics, Future Growth and Outlook 2025-2032 | Mustang Bio, Fate Therapeutics - openPR
Mustang Bio stock plunges to 52-week low of $1.43 By Investing.com - Investing.com Australia
Mustang Bio stock plunges to 52-week low of $1.43 - Investing.com India
Mustang Bio Stock Price, Quotes and Forecasts | NASDAQ:MBIO - Benzinga
Petri Dish: Biotech leaves Worcester; Novo Nordisk, Eli Lilly partnerships - The Business Journals
Mustang Bio Regains Nasdaq Compliance, Secures Position For Cell Therapy Advancements - Nasdaq
Mustang Bio meets Nasdaq’s equity listing requirements By Investing.com - Investing.com Canada
Mustang Bio meets Nasdaq’s equity listing requirements - Investing.com India
Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement - The Manila Times
Mustang Bio, Inc. Regains Compliance with Nasdaq Capital Market Listing Requirements - Nasdaq
Mustang Bio Overcomes Delisting Threat: What This Nasdaq Compliance Means for Investors - StockTitan
Mustang Bio Inc Stock (MBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.78%
0.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):